Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18759613 | 0.89 | HNF4A (0.63) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL30292805 | 0.89 | HNF4A (0.63) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL11554621 | 0.87 | HNF4A (0.61) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL32677772 | 0.85 | HNF4A (0.64) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL505412 | 0.85 | HNF4A (0.64) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL32677769 | 0.85 | HNF4A (0.64) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| Benzene SCHEMBL1403559 | 0.85 | HNF4A (0.69) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| Benzene SCHEMBL28480917 | 0.85 | HNF4A (0.69) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL133057 | 0.85 | HNF4A (0.69) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 | |
| SCHEMBL26624744 | 0.85 | HNF4A (0.69) | HNF4ABCAT2LTB4R2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732669-A | Dicaboxylic acid ligand silver complex and preparation method and application thereof | 曲阜师范大学 | 2016-07-06 | — | — | CN | claimed |
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1144435-B1 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| US-6949570-B2 | Carboxyalkyl substituted sulfonamidomethyl amides or ureas used for treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, and diabetes | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | claimed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | claimed |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ASHWELL SUSAN (US) | 2003-02-06 | — | — | US | claimed |
| US-6436904-B1 | TREATMENT OF INFLAMMATORY DISEASES IN MAMMALS | ELAN PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | claimed |
| US-6407066-B1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | claimed |
| EP-1150997-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| CN-1265668-A | Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| WO-2000043415-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| EP-0994895-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999006435-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| CN-105732669-A | Dicaboxylic acid ligand silver complex and preparation method and application thereof | 曲阜师范大学 | 2016-07-06 | — | — | CN | disclosed |
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | disclosed |
| EP-1501897-B1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF SE (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-5250558-A | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0412594-A2 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | disclosed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | HNF4A 712/4885BCAT2 817/4885LTB4R2 16/4885 |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | HNF4A 726/4885BCAT2 144/4885LTB4R2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.